-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, FCQvxIgLmtO+uiiy6vT3UtB2EodQvouwVsGWExNxivLkaYoNRPUjeIrvJLk2qUE9 F4T+ujdwHnrca5StMN3yfQ== 0001004878-10-000014.txt : 20100113 0001004878-10-000014.hdr.sgml : 20100113 20100113162047 ACCESSION NUMBER: 0001004878-10-000014 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20100111 ITEM INFORMATION: Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review FILED AS OF DATE: 20100113 DATE AS OF CHANGE: 20100113 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CEL SCI CORP CENTRAL INDEX KEY: 0000725363 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 840916344 STATE OF INCORPORATION: CO FISCAL YEAR END: 0930 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-11889 FILM NUMBER: 10525334 BUSINESS ADDRESS: STREET 1: 8229 BOONE BLVD . STREET 2: SUITE 802 CITY: VIENNA STATE: VA ZIP: 22182 BUSINESS PHONE: 7035069460 MAIL ADDRESS: STREET 1: 8229 BOONE BLVD. STREET 2: SUITE 802 CITY: VIENNA STATE: VA ZIP: 22182 FORMER COMPANY: FORMER CONFORMED NAME: INTERLEUKIN 2 INC DATE OF NAME CHANGE: 19880317 8-K 1 form8kitem4021-10.txt 8-K RE ITEM 4.02 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): January 11, 2010 CEL-SCI CORPORATION -------------------------------------------------- (Exact name of Registrant as specified in its charter) Colorado 0-11503 84-0916344 - --------------------------- ----------------------- ----------------- (State or other jurisdiction (Commission File No.) (IRS Employer of incorporation) Identification No.) 8229 Boone Boulevard, Suite 802 Vienna, Virginia 22182 --------------------------------------------------------------------------- (Address of principal executive offices, including Zip Code) Registrant's telephone number, including area code: (703) 506-9460 -------------- N/A ----------------------------------- (Former name or former address if changed since last report) Item 4.02 Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review. On January 11, 2009, CEL-SCI's Chief Executive and Financial Officer determined that there were errors in its 10-Q reports which were filed during the first three quarters of its 2009 fiscal year. The errors, none of which affected the Company source or use of cash, are described below: o During the three months ended December 31, 2008, and March 31, 2009 deferred rent in the amount of $222,527 should have been expensed for each period. However, CEL-SCI did not expense any deferred rent for the three months ended December 31, 2008 or March 31, 2009 but instead expensed deferred rent of $667,581 during the three months ended June 30, 2009. CEL-SCI will amend its 10-Q reports to reflect deferred rent expense of 222,527 for each of these three-month periods. o A derivative liability in the amount of $2,852,666 associated with warrants issued in connection with CEL-SCI's June 2009 financing was recorded as equity instead of a liability. In addition, a loss of $101,166 associated with these warrants should have been expensed at June 30, 2009. CEL-SCI will amend its 10-Q report for the three months ended June 30, 2009 to correct these errors. o The cost, for financial reporting purposes, of $455,000 for extending the expiration date of a warrant should have been recorded as a dividend and not as an expense. CEL-SCI will amend its 10-Q report for the three months ended June 30, 2009 to correct this error. CEL-SCI's Chief Executive, Accounting and Financial Officer has discussed these errors with CEL-SCI's independent accountant. The adjustments which will be made to CEL-SCI's 10-Q reports are reflected in CEL-SCI's financial statements for the year ended September 30, 2009 and are described in Note 14 to such financial statements. It is expected that these financial statements will be filed by January 13, 2010 with CEL-SCI's Form 10-K report. CEL-SCI will file amended 10-Q reports as soon as practicable to reflect the correction of these errors. SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: January 13, 2010 CEL-SCI CORPORATION By: /s/ Geert R. Kersten ---------------------------------------- Geert R. Kersten, Chief Executive Officer -----END PRIVACY-ENHANCED MESSAGE-----